Liege, Belgium, 14 January 2022 – 07:30 CET – Mithra (Euronext Brussels: MITRA), a company
dedicated to Women’s Health, today announces positive efficacy top-line results from Donesta® Phase
3 pivotal “E4 Comfort” clinical trials for the treatment of Vasomotor Symptoms (VMS) in postmenopausal women. Donesta® is Mithra’s next generation orally-administrated estetrol (E4)-based
hormone therapy product candidate.

Liege, Belgium, 13 January 2022 – 7:30 CET – Mithra (Euronext Brussels: MITRA), a company
dedicated to Women’s Health today announces its financial calendar for 2022 :

• 8 March 2022 : 2021 Full Year Results
• 15 April 2022 : 2021 Annual Report
• 19 May 2022 : Annual General Shareholders Meeting
• 23 September 2022 : 2022 Interim report

Liege, Belgium, 10 January 2022 – 7:30 CET – Mithra (Euronext Brussels: MITRA), a company
dedicated to Women’s Health today announces, in accordance with Article 14 of the Belgian Law of
2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted
to trading on a regulated market (the “Transparency Law”), that it received a notification of
transparency from Mr. François Fornieri, on 07 January 2022.